Epidermolysis Bullosa Clinical Trials

4 recruiting

Epidermolysis Bullosa Trials at a Glance

20 actively recruiting trials for epidermolysis bullosa are listed on ClinicalTrialsFinder across 6 cities in 23 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in Paris, Toulouse, and Thessaloniki. Lead sponsors running epidermolysis bullosa studies include Krystal Biotech, Inc., Centre Hospitalier Universitaire de Nice, and Anterogen Co., Ltd..

Browse epidermolysis bullosa trials by phase

Treatments under study

About Epidermolysis Bullosa Clinical Trials

Looking for clinical trials for Epidermolysis Bullosa? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Epidermolysis Bullosa trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Epidermolysis Bullosa clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 20 trials

Recruiting

Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa

Epidermolysis Bullosa Dystrophica
Stanford University70 enrolled1 locationNCT01019148
Recruiting
Phase 2Phase 3

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

Generalized Epidermolysis Bullosa Simplex
TWi Biotechnology, Inc.80 enrolled36 locationsNCT06073132
Recruiting
Phase 1Phase 2

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

Epidermolysis BullosaDystrophic Epidermolysis BullosaEpidermolysis Bullosa Acquisita
M. Peter Marinkovich8 enrolled1 locationNCT06834035
Recruiting
Phase 3

A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa

Dystrophic Epidermolysis BullosaDEB - Dystrophic Epidermolysis Bullosa
Krystal Biotech, Inc.16 enrolled5 locationsNCT07016750
Recruiting

FARD (RaDiCo Cohort) (RaDiCo-FARD)

PemphigusNeurofibromatosis Type 1Ichthyosis+6 more
Institut National de la Santé Et de la Recherche Médicale, France900 enrolled15 locationsNCT05954416
Recruiting
Phase 2

A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study

Dystrophic Epidermolysis BullosaEpidermolysis Bullosa (EB)Junctional Epidermolysis Bullosa
Xinnate AB32 enrolled6 locationsNCT06594393
Recruiting
Phase 3

A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa

Skin DiseasesEpidermolysis BullosaConnective Tissue Disease+7 more
Chiesi Farmaceutici S.p.A.6 enrolled6 locationsNCT06917690
Recruiting
Phase 1Phase 2

Effect of Ev.FV on Wound Healing in Dystrophic Epidermolysis Bullosa

Wound HealDystrophic Epidermolysis Bullosa
Isfahan University of Medical Sciences20 enrolled1 locationNCT07230223
Recruiting

A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez

Epidermolysis Bullosa, DystrophicEpidermolysis Bullosa, Junctional
Amryt Pharma580 enrolled5 locationsNCT06423573
Recruiting
Phase 2

A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex

Epidermolysis Bullosa Simplex
BioMendics, LLC40 enrolled2 locationsNCT07027345
Recruiting
Phase 2

A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses

IchthyosisEpidermolysis Bullosa SimplexGenodermatosis+1 more
Centre Hospitalier Universitaire de Nice10 enrolled2 locationsNCT06136403
Recruiting

A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)

Epidermolysis Bullosa DystrophicaEpidermolysis Bullosa Dystrophica, RecessiveEpidermolysis Bullosa Dystrophica Dominans
Krystal Biotech, Inc.40 enrolled1 locationNCT06563414
Recruiting
Phase 1Phase 2

MSC EVs in Dystrophic Epidermolysis Bullosa

Dystrophic Epidermolysis Bullosa
Aegle Therapeutics8 enrolled3 locationsNCT04173650
Recruiting

Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling

Quality of LifeTuberous SclerosisBirt-Hogg-Dube Syndrome+7 more
Maastricht University Medical Center25 enrolled1 locationNCT06330350
Recruiting
Phase 2

A 20-Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex Generalized

Epidermolysis Bullosa SimplexGenodermatosis
Centre Hospitalier Universitaire de Nice20 enrolled4 locationsNCT06509984
Recruiting

Study of the Blood and Skin Immunological Profile of Patients With Recessive Dystrophic Epidermolysis Bullosa: in Vivo Analysis and the Impact of Placental Stem Cells in Vitro

Epidermolysis Bullosa Dystrophica
Assistance Publique - Hôpitaux de Paris30 enrolled2 locationsNCT06177353
Recruiting
Phase 2

Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa

Dystrophic Epidermolysis Bullosa
Anterogen Co., Ltd.6 enrolled1 locationNCT05157958
Recruiting

Long-Term Follow-up Protocol

Dystrophic Epidermolysis Bullosa
Krystal Biotech, Inc.50 enrolled3 locationsNCT04917887
Recruiting
Phase 1Phase 2

Gentamicin for Junctional Epidermolysis Bullosa

Junctional Epidermolysis Bullosa
University of Southern California6 enrolled1 locationNCT03526159
Recruiting

An Australian Study assessing the effects of Avene Thermal Water Spray in patients with recessive dystrophic epidermolysis bullosa

Epidermolysis Bullosa
Professor Dedee Murrell20 enrolled1 locationACTRN12611000677909